Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 US Manufacturing
Filings indexed 991 across all filing types
Latest filing 2026-05-07 Prospectus
Country US United States of America
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
424B5 - RedHill Biopharma Ltd. (0001553846) (Filer)
Prospectus
2026-05-07 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Foreign Filer Report
2026-04-30 English
20-F - RedHill Biopharma Ltd. (0001553846) (Filer)
Annual Report
2026-04-27 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Foreign Filer Report
2026-04-27 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Foreign Filer Report
2026-04-22 English
6-K - RedHill Biopharma Ltd. (0001553846) (Filer)
Foreign Filer Report
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.